PURPOSE: To compare Borrelia-specific intrathecal antibodies by two different ELISAs, an immunoblot (IB) and @entity14638 . METHODS: Twenty-seven adults and 23 @entity1 with clinical symptoms compatible with NB were tested for Borrelia-specific intrathecal antibodies by flagellum ELISA-AI (flELISA), a recombinant ELISA-AI (rELISA) and by IB. @entity1 were classified according to the European Federation of Neurological Societies (EFNS) criteria as definite NB, possible NB, or non-NB. CSF @entity14638 levels were measured by ELISA. RESULTS: Among 50 @entity1 , definite NB was diagnosed with the rELISA-AI in 29 (58%) @entity1 , confirmed by IB in 19/29 @entity1 , with flELISA-AI in 17 (34%) @entity1 , confirmed by IB in 15/17 @entity1 , and with IB in 20 (40%) @entity1 . @entity14638 was positive in 22 (44%) @entity1 . In 4 of 8 @entity1 with negative AI, IB showed many detectable bands both in the CSF and serum. CONCLUSIONS: The diagnosis of NB strongly relies on the used test method. The rELISA-AI test appears to be the most sensitive while the flELISA-AI is the least sensitive. However when the ELISA-AIs were confirmed by IB, different @entity1 were identified as NB, while only 26% were identified by all performed test methods. There is a demand for standardized test methods with well-defined sensitivity and specificity to establish validated diagnostic criteria for NB including the use of the IB assay and @entity14638 as an additional non-Borrelia specific @entity204 .

Laboratory diagnosis of Lyme neuroborreliosis is influenced by the test used: Comparison of two ELISAs, immunoblot and XXXX testing.

@entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients'] @entity14638 :: ('10563', 'Gene') :: ['CXCL13'] @entity204 :: ('MESH:D003643', 'Disease') :: ['determinant in early NB']
@entity14638 :: (10563,Gene) :: ['CXCL13']
